Navigation Links
Arpida Announces Full Year 2008 Financial Results
Date:2/25/2009

p a roadmap to approval.

The regulatory filing in the European Union is ongoing. Arpida has received an intermediate report from the European Medicines Agency (EMEA) containing the findings of the review carried out so far. The company is working closely with EMEA to address the topics it has put forward.

The Canadian filing is currently not being pursued.

Oral iclaprim in cSSSI - in-depth analysis ongoing for further design of development plan

In December 2008, Arpida announced the top-line results of a Phase II "intravenous-to-oral" switch trial with iclaprim in patients with cSSSI. In parallel with the Phase II trial, the last ongoing study of the Phase I programme has been closed.

Based on the review to date, Arpida expects that further development work will be required in order to better understand the effect of orally administrated iclaprim on liver enzymes and to explore optimal dosing regimens.

Other programmes:

In December 2008, a re-alignment of activities was initiated. The action plan to reduce costs impacts the development programmes in different ways:

    - study stopped: Phase II with intravenous iclaprim in HAP/VAP/HCAP
    - late preclinical studies stopped: AR-709 and AR-2474
    - trial ongoing, further patient enrolment stopped: Phase III study with
      TLT in onychomycosis.

A PDF-file containing the preliminary 2008 annual report (in English) is available on our website (http://www.arpida.com) starting 25 February 2009, noon.

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the
'/>"/>

SOURCE Arpida Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Arpida Interim Results for six Months to 30 June 2007
2. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
3. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
4. Arpida Presents Preclinical Data on AR-2474 at ICAAC
5. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
6. Arpida-Supported CME Symposium Available Online
7. Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
8. Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis
9. Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim
10. Arpida Announces Full Year 2007 Financial Results
11. Arpida Submits New Drug Application for Intravenous Iclaprim for Treatment of Skin Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 04, 2015 Genedata, a leading ... and life science research, today announced the release ... version of its enterprise solution for biologics R&D. ... more efficient discovery and development of novel biotherapeutics. ... and address protein optimization and developability requirements. Genedata ...
(Date:5/4/2015)... 4, 2015   Tocagen Inc. , a ... from Tocagen,s ongoing investigational studies were presented at ... American Association of Neurological Surgeons (AANS)/Congress of Neurological ... 2015, in Washington, D.C. ... meeting with FDA and continues to advance towards ...
(Date:5/1/2015)... May 01, 2015 OncoTAb, Inc., ... Charlotte) spin-out company, announced that Pinku Mukherjee, Ph.D. has ... UNC Board of Governors’ highest faculty honor. Mukherjee received ... welfare , for her innovative research and development of ... Award represents a crowning moment in my scientific career,” ...
(Date:5/1/2015)... LONDON , May 1, 2015 ... following equities: Genetic Technologies Ltd (NASDAQ: GENE ... Thermo Fisher Scientific Inc. (NYSE: TMO ), ... Inc. (NYSE: PKI ). Free research report ... http://get.Investor-Edge.com/pdf/?c=Genetic%20Technologies&d=01-May-2015&s=GENE . On Thursday, April 30, 2015, the ...
Breaking Biology Technology:Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 2Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 3Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 4Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 2Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 3Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 4Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 5OncoTAb CSO Awarded the University of North Carolina’s O. Max Gardner Award 2Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 2Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 3Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 4Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 5
... , BRISBANE, Calif., Oct. 29 InterMune, Inc. (Nasdaq: ... 2009 financial results on Thursday, November 5, 2009 at 4:00 ... will be hosted by InterMune at 4:30 p.m. Eastern time ... 888-799-0528 (U.S.) or 973-200-3372 (international), conference ID# 37626791. To ...
... SOLANA BEACH, Calif. & HAMILTON, New Zealand, Oct. 29 ... products for DNA extraction and other life sciences applications, ... with VERITAS Japan to distribute ZyGEM,s DNA extraction products ... the latest in a series of recent major distribution ...
... Calif., Oct. 29 NeurogesX, Inc. (Nasdaq: NGSX ... novel pain management therapies, announced today that Anthony DiTonno, ... at two upcoming conferences in New York City: the ... held November 3-4, 2009 and the Lazard Capital Markets ...
Cached Biology Technology:InterMune to Release Third Quarter Financial Results on November 5 2ZyGEM Strengthens its Worldwide Presence With New Distribution Agreement for Japan 2ZyGEM Strengthens its Worldwide Presence With New Distribution Agreement for Japan 3ZyGEM Strengthens its Worldwide Presence With New Distribution Agreement for Japan 4NeurogesX to Present at Two November Conferences 2NeurogesX to Present at Two November Conferences 3
(Date:4/14/2015)... Conn. , April 14, 2015 NXT-ID, ... a biometric authentication company focused on the growing mobile ... been nominated for the 2015 New York Design Awards ... The Design100, New York City Design Awards are part ... based on over 2,500 ratings from the marketplace, industry ...
(Date:4/8/2015)... 2015  Infinisource, a leading provider of SaaS-based Human ... a leading supplier of biometric identification and security ... most advanced biometrically-enabled time clock, the companies announced ... is setting a bold, new standard for the ... small and mid-size employer. When connected to the ...
(Date:4/2/2015)... GOTHENBURG, Sweden , April 2, 2015 ... for its touch fingerprint sensor FPC1025 from the distributor ... Deliveries will commence during Q2 2015 although the major ... 2015. The sensors will be used by smartphone manufacturers ... of 110 MSEK is included in the communicated revenue ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2
... of bacterial communication may have been found. Although they ... about what,s going on in their neighborhood and communicate with ... their surrounding environment. Even though there are millions of different ... world around them, Duke University bioengineers believe they have found ...
... on detecting short, repetitive DNA segments in the genome ... repeats. "With this method we are able to identify ... Furthermore, we can show how new pathogenic variants develop," ... have now been published in the current issue of ...
... mothers suggests that a group of common environmental contaminants ... consumer products including everyday personal care items, may contribute ... Researchers at the University of Michigan School of ... on average, up to three times the phthalate level ...
Cached Biology News:Finding the constant in bacterial communication 2Finding the constant in bacterial communication 3The tiny difference in the genes of bacteria 2Chemicals in common consumer products may play a role in pre-term births 2
Mouse polyclonal antibody to QPRT - quinolinate phosphoribosyltransferase (nicotinate-nucleotide pyrophosphorylase (carboxylating))...
... Optimization Kits without ammonium sulfate are compatible ... such as Taq and AmpliThem™™ DNA polymerases. ... PCR systems in one experiment by adding ... into the PreMixes supplied with the kit. ...
Application: for RNase- decontamination , Registered Trademark of Ambion. ,Special grade: for molecular biology Density: 1.00 g/mL (20 C) Suitab tst: RNase decontamination in accordance...
... A cleaning agent for removing ... countertops, and pipettors. It ... RNase contamination from microcentrifuge tubes ... ,RNase Zap (R) ...
Biology Products: